Actively Recruiting
Phase 2 Evaluation of Cemsidomide and Dexamethasone Treatment in Adults with Relapsed or Refractory Multiple Myeloma
Led by C4 Therapeutics, Inc. · Updated on 2026-08-06
100
Participants Needed
21
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the activity and safety of cemsidomide combined with dexamethasone in adults with relapsed or refractory multiple myeloma. This Phase 2, open-label, single-arm, multicenter study aims to understand how well this combination works and to characterize its safety, tolerability, pharmacokinetics, and pharmacodynamics. Participants receive cemsidomide orally once daily for 14 days followed by 14 days off in each 28-day cycle. Dexamethasone is taken orally once weekly on Days 1, 8, 15, and 22 of each cycle. Treatment continues in 28-day cycles until discontinuation criteria are met. During the study, participants undergo regular assessments to measure response rates, duration and time to response, progression-free survival, and overall survival. Safety is monitored through reporting of adverse events and laboratory tests. The study also tracks cemsidomide plasma levels. Participation may last up to approximately 43 months, with safety follow-up occurring within about 30 to 35 days after the last dose.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Research Team
S
Study Medical Officer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
